gsk

ViiV Healthcare’s long-acting HIV treatment Cabenuva (cabotegravir + rilpivirine) meets primary endpoint of superior viral suppression vs. daily oral therapy in people with ...

CROWN is the first large, phase IIIb international trial to evaluate the investigational use of long-acting Cabenuva versus daily oral therapy in people with a history of antiretroviral treatment and ...
gsk

Ris-Rez reduced risk of death by 54% versus topotecan in patients with relapsed small cell lung cancer in China

GSK plc (LSE/NYSE: GSK) licensor Hansoh Pharmaceutical Group Co., Ltd., today announced positive overall survival (OS) data from ARTEMIS-008, its pivotal phase III trial in China evaluating the ...
gsk

GSK delivers strong Q2 core results performance and continued momentum. Plans announced to accelerate R&D and late-stage pipeline portfolio. Expect 20+ phase III trial starts ...

Specialty Medicines sales £3.8 billion (+14%); Respiratory, Immunology & Inflammation £1.1 billion (+19%); Oncology £0.6 billion (+17%); HIV sales £2.1 billion (+10%) Vaccines sales £2.3 billion (+8%) ...
gsk

GSK announces commencement of tender offer to acquire Nuvalent, Inc.

GSK plc (LSE/NYSE: GSK) today announced that Harmony Row Acquisition Co. (“Purchaser”), a direct wholly-owned subsidiary of ‎GlaxoSmithKline LLC (“GSK LLC”), which is an ‎indirect wholly-owned ...
gsk

GSK’s momelotinib granted Orphan Drug Designations in the US and EU for VEXAS syndrome

VEXAS syndrome is a rare, life-threatening haemato-inflammatory condition with no approved treatments ATLAS phase II/III trial in VEXAS underway, advancing momelotinib’s broader development programme ...
gsk

GSK enters agreement to acquire Nuvalent, Inc.

Multi-product oncology deal for assets that have validated targets and aim to address efficacy and/or tolerability limitations of existing therapies Includes two late-stage, potential best-in-class ...
gsk

GSK delivers strong Q1 performance and start to 2026

Luke Miels, Chief Executive Officer, GSK: “GSK has made a strong start to 2026, with good performance from our key growth drivers. Alongside operational delivery, we are focused on execution and ...
gsk

Blenrep (belantamab mafodotin) approved in China for treatment of 2L+ relapsed/refractory multiple myeloma

Blenrep is a monoclonal ADC comprising a humanised BCMA conjugated to the cytotoxic agent monomethyl auristatin F via a non-cleavable linker. The drug linker technology is licensed from Seagen Inc.; ...
gsk

GSK completes acquisition of 35Pharma Inc.

GSK plc (LSE/NYSE: GSK) today announced the completion of its acquisition of 35Pharma Inc., a Canada-based, private, clinical-stage biopharmaceutical company specialising in the development of novel ...
gsk

Exdensur (depemokimab) approved in China for the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP)

Exdensur is the first and only ultra-long-acting biologic in China for CRSwNP Approval based on ANCHOR trials showing clinically meaningful and statistically significant improvements in nasal polyp ...
gsk

GSK and Alfasigma announce agreement on worldwide rights for linerixibat

GSK plc (LSE/NYSE: GSK) and Alfasigma S.p.A. today announced a licence agreement under which Alfasigma will acquire worldwide exclusive rights to develop, manufacture and commercialise linerixibat, an ...
gsk

Exdensur (depemokimab) approved by the European Commission for severe asthma with type 2 inflammation and chronic rhinosinusitis with nasal polyps

Exdensur is the first and only ultra-long-acting biologic in the EU to treat respiratory diseases Approval based on four phase III trials with statistically significant and clinically meaningful ...